ANSWER: C

Rationale:

This question asked you to apply the nitrate-PDE-5 inhibitor contraindication under acute clinical pressure. Option C is correct: sildenafil use within 24 hours is an absolute contraindication to nitrate administration — there is no dose reduction, route modification, or monitoring arrangement that makes this combination safe. Sildenafil inhibits phosphodiesterase type 5 (PDE-5), the enzyme that degrades cyclic GMP (cGMP) in vascular smooth muscle. Organic nitrates generate NO, which activates soluble guanylate cyclase and produces cGMP. When PDE-5 is blocked, the cGMP produced by the nitrate accumulates to levels that cause profound, uncontrolled systemic vasodilation. The resulting hypotension can be catastrophic, refractory to standard vasopressor therapy, and potentially fatal. At 14 hours post-sildenafil, the drug's half-life of approximately 4 hours means that plasma concentrations are falling but PDE-5 inhibitory activity sufficient to produce a dangerous interaction with nitrates remains — the 24-hour window for sildenafil (and 48 hours for tadalafil, which has a longer half-life) is the clinically conservative and appropriate threshold. In this patient, acute management proceeds without nitrates: aspirin has already been given; anticoagulation (heparin or bivalirudin) should be initiated; the catheterization laboratory should be activated immediately for primary PCI, which is the definitive treatment for STEMI; morphine can be considered for pain control with awareness of its own hemodynamic effects.

• Option A: Option A is incorrect: there is no evidence that half-dose nitroglycerin is safe after recent PDE-5 inhibitor use; the contraindication is pharmacodynamic and does not scale proportionally with dose — even small amounts of nitrate can produce catastrophic hypotension when cGMP degradation is blocked.
• Option B: Option B is incorrect: the contraindication window for sildenafil is 24 hours, not 12 hours; 14 hours does not clear the contraindication; the FDA prescribing information and ACC/AHA guidelines specify 24 hours for sildenafil and vardenafil.
• Option D: Option D is incorrect: the route of administration does not change the pharmacodynamic interaction; intravenous nitroglycerin generates the same cGMP-elevating mechanism as sublingual nitroglycerin, and the ability to titrate or discontinue infusion does not prevent the interaction from producing severe hypotension before the infusion can be stopped.
• Option E: Option E is incorrect: intravenous verapamil is not indicated in acute STEMI and would be actively harmful — negative inotropy in the setting of acute myocardial ischemia and ongoing infarction can cause hemodynamic collapse; non-DHP CCBs are not equivalent to nitrates for acute symptom control in STEMI.

ANSWER: E

Rationale:

This question asked you to diagnose right ventricular infarction, explain the nitrate contraindication, and identify the correct treatment. Option E is correct: the clinical triad of inferior STEMI with hypotension, elevated jugular venous pressure (JVP), and clear lungs is the classic presentation of right ventricular infarction. The right coronary artery, which supplies the inferior wall of the left ventricle in right-dominant circulation (approximately 85% of patients), also supplies the right ventricle via the right ventricular marginal branches. When the right coronary artery is occluded proximally in an inferior STEMI, the right ventricle infarcts along with the inferior left ventricular wall. The infarcted right ventricle loses contractile function and becomes entirely dependent on elevated filling pressures — high preload — to generate sufficient forward output across the pulmonary circulation to fill the left ventricle. Elevated JVP reflects the increased right-sided pressures required to maintain this marginal output. Clear lungs confirm that the problem is right-sided failure (inadequate forward output from RV to pulmonary circulation), not left-sided failure with pulmonary congestion. Nitroglycerin is absolutely contraindicated: venodilation reduces venous return, dropping right ventricular preload, and in a preload-dependent right ventricle this precipitates immediate hemodynamic collapse. The correct treatment is aggressive intravenous fluid resuscitation — typically 1–2 liters of normal saline — to restore right ventricular preload and maintain forward output. Diagnosis is confirmed by right-sided ECG leads, with ST elevation in V4R being the most sensitive and specific finding.

• Option A: Option A is incorrect: clear lungs exclude left ventricular failure with pulmonary congestion; elevated JVP with clear lungs is the signature of right-sided failure, not LV failure; nitroglycerin at low doses with vasopressor support is not the appropriate management.
• Option B: Option B is incorrect: while inferior STEMI does cause bradycardia and heart block (through increased vagal tone and AV node ischemia), the clinical picture here — elevated JVP, clear lungs, and severe hypotension — indicates RV infarction as the primary hemodynamic problem, not isolated heart block; nitroglycerin is not vagolytic and does not affect ventricular escape rate.
• Option C: Option C is incorrect: RV infarction is an absolute, not relative, contraindication for nitroglycerin; vasopressor support does not make nitrate administration safe in this setting; dobutamine may be considered if fluid resuscitation is insufficient, but it is not the first-line treatment.
• Option D: Option D is incorrect: hemopericardium causing tamponade is a recognized mechanical complication of MI but typically presents with equalization of diastolic pressures across all chambers, pulsus paradoxus, and a different ECG pattern; the inferior STEMI distribution and right-sided hemodynamic findings fit RV infarction more precisely.

ANSWER: A

Rationale:

This question asked you to apply current evidence-based guidance on beta-blocker use in peripheral artery disease. Option A is correct: the historical concern that beta-blockers worsen peripheral artery disease by blocking beta-2-mediated vasodilation in skeletal muscle arterioles — leaving alpha-1-mediated vasoconstriction unopposed — has not been validated in clinical evidence. Multiple trials and meta-analyses have demonstrated that cardioselective beta-blockers do not significantly worsen claudication distance, ankle-brachial index, or functional capacity in patients with stable PAD. Current ACC/AHA guidelines for both stable ischemic heart disease and peripheral artery disease explicitly state that beta-blockers are not contraindicated in PAD and should be used when indicated for coronary artery disease. This is clinically important: patients with both coronary artery disease and PAD represent a high-risk population with advanced systemic atherosclerosis, and beta-blocker-associated cardiovascular mortality reduction is potentially even more important in this group. Cardioselective agents (metoprolol, atenolol, bisoprolol) are preferred to minimize any theoretical beta-2 peripheral vascular effect. The patient's refusal based on an outdated contraindication should be addressed with reassurance and education. Option D invents an ABI-based threshold (0.8 cutoff) for beta-blocker contraindication that does not exist in any major guideline; the contraindication concern is not stratified by ABI value.

• Option B: Option B incorrectly states an absolute contraindication that does not exist in current guidelines; the concern about beta-2 blockade worsening claudication is theoretical and has not been validated in clinical trials of cardioselective agents in stable PAD.
• Option C: Option C incorrectly classifies beta-blockers as relatively contraindicated in PAD and proposes substituting amlodipine monotherapy; while amlodipine does improve peripheral blood flow and is beneficial in PAD-associated hypertension, it does not provide the cardiovascular mortality benefit of beta-blockers post-MI or in stable ischemic heart disease, and is not an appropriate substitute when beta-blockers are indicated.
• Option E: Option E is incorrect: there is no requirement to combine beta-blockers with DHP-CCBs in PAD; the beta-blocker is not contraindicated in PAD and does not require a mandatory vasodilatory "antidote" for peripheral vascular protection.

ANSWER: B

Rationale:

This question asked you to explain why beta-blockers specifically lead the antianginal regimen after MI. Option B is correct: beta-blockers hold the first-line position in post-MI antianginal therapy because they are the only antianginal drug class that provides both anti-ischemic benefit and proven mortality reduction in this setting. The anti-ischemic mechanisms are well-established: beta-1 blockade at the SA node reduces heart rate (the most powerful anti-ischemic lever), beta-1 blockade at cardiac myocytes reduces contractility, and the resulting heart rate reduction prolongs diastole, improving coronary perfusion — together these substantially lower MVO2 and improve the supply-demand balance. Beyond anti-ischemic benefit, post-MI beta-blocker trials established a significant reduction in all-cause mortality, sudden cardiac death (through antiarrhythmic effects), and reinfarction risk — benefits that persist across a broad range of ejection fractions including mildly reduced function such as this patient's EF of 48%. This dual benefit — symptom control plus mortality modification — is unique among antianginal drug classes: nitrates control symptoms but do not reduce post-MI mortality; dihydropyridine CCBs control symptoms and are hemodynamically neutral in reduced EF but do not improve survival; ranolazine reduces symptoms without mortality benefit. The beta-blocker is therefore not merely the most effective anti-ischemic option post-MI — it is the only option that simultaneously protects against the life-threatening sequelae of the underlying coronary disease. Option C contains a partial truth — beta-blockers do reduce adverse LV remodeling after MI through neurohumoral blockade — but this is not the primary reason beta-blockers lead antianginal therapy; the mortality benefit and anti-ischemic efficacy are the primary drivers, and the remodeling benefit is a related but distinct indication.

• Option A: Option A is incorrect: beta-blockers do not inhibit platelet aggregation through beta-receptor mechanisms; antiplatelet effects are the domain of aspirin and P2Y12 inhibitors; this is a fabricated mechanism.
• Option D: Option D incorrectly attributes afterload reduction to beta-2 peripheral vasodilation as a mechanism of beta-blockers; beta-blockers do not reduce afterload as a primary mechanism; afterload reduction is achieved by vasodilating agents such as CCBs and nitrates.
• Option E: Option E is incorrect: the mortality benefit of beta-blockers post-MI applies across the ejection fraction spectrum including mildly reduced function; there is no guideline threshold of EF below 40% that restricts beta-blocker preference in post-MI antianginal therapy; and nitrate monotherapy as first choice in post-MI patients with EF of 48% is not supported by evidence or guidelines.

ANSWER: D

Rationale:

This question asked you to explain the significance of silent ischemia in a diabetic patient and justify treatment in the absence of symptoms. Option D is correct: this patient has silent myocardial ischemia — objectively demonstrated myocardial ischemia (2 mm horizontal ST depression at a reproducible exercise workload) in the complete absence of anginal symptoms. Silent ischemia is particularly common in diabetic patients because diabetic autonomic neuropathy impairs afferent cardiac pain fiber function, blunting the perception of ischemia-related discomfort even when the underlying metabolic and mechanical cascade of ischemia is fully active. Recall from the ischemic cascade that symptoms are the last manifestation of ischemia — metabolic changes, diastolic dysfunction, systolic dysfunction, and ECG changes all precede symptom onset. In a diabetic patient with autonomic neuropathy, the symptom threshold may be so elevated that it is never reached even during significant ischemia. This means symptom-guided management — treating only when the patient reports chest pain — will systematically undertreat his ischemic burden. Antianginal therapy is indicated: the hemodynamic targets (resting heart rate 55–60 bpm, RPP reduced ≥15–20% from baseline) apply regardless of whether ischemia is symptomatic or silent, because the goal is to keep the rate-pressure product below the objectively documented ischemic threshold, not merely to relieve symptoms. Option E is pharmacologically and clinically incorrect: there is no evidence or guideline that recommends withholding antianginal therapy in asymptomatic ischemia to preserve a "warning signal"; treating silent ischemia to hemodynamic targets does not increase MI risk and the premise is not supported by any cardiovascular evidence base.

• Option A: Option A is incorrect: 2 mm horizontal ST depression at peak exercise with recovery over 4 minutes is not attributable to autonomic neuropathy-related baseline changes; this is a significant positive stress test result that warrants clinical action, not reassurance.
• Option B: Option B overstates the diagnostic implication: 2 mm ST depression during exercise does not automatically indicate severe three-vessel disease requiring immediate revascularization; further risk stratification (imaging, coronary CT angiography, or invasive angiography depending on pre-test probability and functional capacity) may be appropriate, but withholding antianginal pharmacotherapy is not supported.
• Option C: Option C incorrectly attributes the ST depression to LVH-related changes rather than ischemia; while LVH can produce resting ST abnormalities, the dynamic exercise-induced 2 mm horizontal ST depression with recovery pattern is the characteristic ECG signature of exercise-induced ischemia and should not be dismissed.

ANSWER: C

Rationale:

This question asked you to identify the appropriate next step when angina remains refractory despite optimal triple antianginal therapy. Option C is correct: this patient has CCS Class III stable angina that persists despite maximally tolerated triple conventional therapy — beta-blocker at target heart rate, DHP-CCB at maximum dose, and long-acting nitrate — with all four pharmacological levers engaged. Pharmacological antianginal therapy has a definable ceiling: beyond optimal doses of three complementary agents, further drug additions produce diminishing anti-ischemic returns while accumulating adverse effects and drug interactions. ACC/AHA guidelines for stable ischemic heart disease identify persistent angina limiting ordinary physical activity (CCS Class III) despite optimal medical therapy as a Class I indication for coronary angiography to define anatomy and assess revascularization candidacy. Revascularization — PCI or CABG depending on coronary anatomy, lesion complexity, and patient characteristics — can relieve ischemia at its anatomical source in a way that pharmacological therapy cannot, and is appropriate when medical therapy has been genuinely optimized and symptoms remain unacceptable. Option A is not incorrect as a short-term step — ranolazine does add non-hemodynamic anti-ischemic benefit and could be trialed — but indefinitely adding drug after drug before referring for revascularization assessment in a Class III patient on triple therapy delays guideline-indicated invasive evaluation and is not the most appropriate next step when the hemodynamic ceiling has clearly been reached.

• Option B: Option B is incorrect: metoprolol 400 mg daily exceeds the standard maximum dose range, and increasing above the beta-receptor saturation point adds toxicity without additional anti-ischemic benefit; the premise that patients have not reached a pharmacological ceiling at guideline-maximum doses of triple therapy is not supported.
• Option D: Option D is incorrect: spironolactone is not an established antianginal agent for refractory stable angina; it has no proven role in reducing anginal frequency in this context; the claim of multiple randomized trials supporting this indication for spironolactone in stable angina does not reflect the evidence base.
• Option E: Option E is incorrect: advising activity restriction below the anginal threshold treats the symptom by avoiding it rather than addressing the underlying ischemia; activity reduction does not modify cardiovascular risk, and deferring invasive assessment for three months in a CCS Class III patient on maximal medical therapy represents inappropriate delay.

ANSWER: E

Rationale:

This question asked you to identify the preferred antianginal approach for vasospastic angina in pregnancy. Option E is correct on multiple levels: calcium channel blockers are the established first-line pharmacological treatment for vasospastic angina in all patients, including pregnant women, because they directly address the pathological calcium-mediated coronary smooth muscle hyperreactivity responsible for spasm. Among the antianginal drug classes, CCBs have accumulated the most reassuring pregnancy safety data — nifedipine is extensively used in obstetric practice as a tocolytic and antihypertensive agent, providing substantial real-world safety data across gestational ages. Verapamil is also used in pregnancy for maternal arrhythmias. While no antianginal agent has a perfect pregnancy safety record, CCBs represent the best balance of pharmacological efficacy for vasospasm and fetal safety evidence. Beta-blockers are used in pregnancy for maternal cardiac indications but carry associations with fetal growth restriction (reduced uteroplacental blood flow from beta-2 blockade in uterine vasculature), neonatal bradycardia, hypoglycemia, and respiratory depression when used near delivery — requiring careful monitoring. Additionally, beta-blockers are specifically contraindicated for vasospastic angina regardless of pregnancy status, making them doubly inappropriate here. Long-acting nitrates have limited pregnancy safety data and are generally avoided when alternatives exist. Ranolazine has insufficient human pregnancy safety data.

• Option A: Option A is incorrect for two reasons: beta-blockers are contraindicated in vasospastic angina (beta-2 blockade worsens spasm) regardless of pregnancy, and propranolol's non-selectivity makes it particularly inappropriate; the premise that propranolol concentrations reaching the fetus are insufficient to cause effects is incorrect.
• Option B: Option B is incorrect: while NO is an important placental vasodilator, this does not make exogenous organic nitrate administration equivalent to physiological NO production or free of risk; nitrates have limited pregnancy safety data and are not the preferred agent for vasospastic angina in pregnancy.
• Option C: Option C is incorrect: ranolazine has inadequate human pregnancy safety data and is not a preferred antianginal in pregnancy; the pharmacokinetic reasoning about placental crossing is speculative and does not constitute established safety.
• Option D: Option D is incorrect: vasospastic angina in pregnancy can cause significant myocardial ischemia and requires active pharmacological management; complete bed rest and avoidance of triggers alone is insufficient and potentially dangerous management.

ANSWER: A

Rationale:

This question asked you to correctly identify nitrate-induced headache and flushing as a pharmacological adverse effect and provide appropriate counseling. Option A is correct: the severe throbbing headache and flushing experienced after sublingual nitroglycerin are the classic, predictable pharmacological adverse effects of organic nitrates — not an allergic reaction. The mechanism is identical to the therapeutic mechanism: nitric oxide released from the drug activates soluble guanylate cyclase and generates cGMP in vascular smooth muscle throughout the body, including meningeal vessels and facial skin vasculature. Meningeal vasodilation produces the characteristic throbbing headache (similar in quality to a vascular or migraine headache); facial vascular dilation produces flushing and warmth. These effects are dose-related and universal to organic nitrates. Critically, these are not signs of hypersensitivity or allergic reaction — no IgE-mediated mechanism is involved, and the patient does not require epinephrine or emergency evaluation. She should be reassured with three specific points: first, the drug worked as intended (chest pressure resolved in two minutes, confirming anti-ischemic efficacy); second, the headache and flushing are expected pharmacological effects; and third, tolerance to the cephalic vascular effects typically develops within days to weeks of regular use, while the anti-ischemic effect is maintained. Acetaminophen taken at the time of future doses is an effective and safe strategy to manage headache severity.

• Option B: Option B is incorrect: true allergic hypersensitivity reactions to organic nitrates are exceedingly rare; the headache and flushing described are the characteristic pharmacological adverse effect profile, not anaphylaxis; epinephrine auto-injectors and nitrate avoidance are not indicated.
• Option C: Option C is incorrect: a throbbing headache after nitroglycerin is not caused by cerebral hypoperfusion; while nitrates can reduce blood pressure and cause postural hypotension, the headache in this case is vascular (meningeal dilation) rather than ischemic; emergency department evaluation is not required for the described presentation.
• Option D: Option D is incorrect: dose-based weight adjustment for nitroglycerin headache is not a standard clinical approach; there is no evidence-based 0.2 mg threshold based on body weight, and a pain score threshold for emergency evaluation is not an appropriate clinical guideline for pharmacological nitrate headache.
• Option E: Option E is incorrect: one episode of nitroglycerin use cannot cause medication overuse headache, which requires chronic frequent use over weeks to months; the headache occurred acutely after the dose and is mechanistically explained by meningeal vasodilation.

ANSWER: B

Rationale:

This question asked you to identify the specific orthostatic hypotension risk of adding a long-acting nitrate in an elderly patient with pre-existing postural instability and outline the appropriate management approach. Option B is correct: this patient is at high risk for a clinically serious adverse event from adding isosorbide mononitrate. She has three concurrent vasodilating mechanisms already operating: amlodipine dilates peripheral arterioles (afterload reduction), metoprolol reduces cardiac output reserve (blunting the compensatory tachycardia response to postural change), and her pre-existing 30 mmHg orthostatic drop with symptoms indicates already-compromised postural blood pressure regulation. Adding ISMN engages a fourth vasodilating mechanism — venodilation of large capacitance veins — reducing venous return and further impairing the orthostatic blood pressure response. The clinical consequences in an elderly patient living alone with a recent fall history could be severe: a syncopal or near-syncopal fall after rising from bed could result in hip fracture or head injury. If the nitrate is clinically necessary for angina control, appropriate risk mitigation includes: using the lowest effective dose; measuring orthostatic blood pressure lying and standing before and after the first dose; counseling the patient to remain seated at the bedside for one to two minutes before standing after each morning dose; reinforcing strict alcohol avoidance (alcohol independently contributes to vasodilation and impairs compensatory postural reflexes); and considering whether a fall alert device or social support is needed.

• Option A: Option A overstates the contraindication to an absolute prohibition and incorrectly positions ranolazine as a universal safe substitute; while ranolazine does have favorable hemodynamics, the decision to use or withhold nitrates in this context requires clinical judgment, not a blanket contraindication, and ranolazine is not the default substitute for nitrates in all elderly patients.
• Option C: Option C is incorrect: venodilation and arteriolar dilation are mechanistically distinct but hemodynamically additive — both reduce cardiac preload and impair the blood pressure response to standing; the claim that different vascular compartments means no interaction is pharmacologically incorrect.
• Option D: Option D is incorrect: bedtime dosing of a long-acting nitrate would maintain drug levels overnight and eliminate the nitrate-free interval, causing tolerance; furthermore, nighttime dosing does not eliminate fall risk because the patient must still rise during the night for the bathroom — a common fall scenario in elderly patients.
• Option E: Option E inverts the nitrate mechanism: long-acting nitrates dilate capacitance veins, increasing venous pooling in dependent vessels and reducing venous return — the opposite of improving orthostatic stability; they do not reduce peripheral venous pooling.

ANSWER: D

Rationale:

This question asked you to explain the specific hemodynamic risk of nitrates in severe aortic stenosis. Option D is correct: the fundamental hemodynamic vulnerability in severe aortic stenosis is the fixed mechanical obstruction at the valve level. In a normal cardiovascular system, when nitrate-induced venodilation reduces preload and venous return, the heart compensates by multiple mechanisms — including reflex tachycardia, peripheral vasoconstriction, and increased contractility — to maintain cardiac output. Crucially, the heart can also augment stroke volume if needed, since the outflow tract is unobstructed. In severe aortic stenosis, however, the stenotic valve creates a fixed, non-modifiable resistance to outflow. The left ventricle cannot increase stroke volume across a valve area of 0.7 cm² regardless of compensatory effort — the physical orifice determines the maximum flow that can be achieved at any given pressure gradient. When nitrates reduce preload (lowering LVEDV and LVEDP), the ventricle has less volume to eject across this fixed obstruction, and since it cannot compensate by augmenting stroke volume through the valve, cardiac output falls precipitously. The result can be severe, sudden, and potentially refractory hypotension — a hemodynamic emergency. This is why nitrates are used with extreme caution or avoided in severe aortic stenosis, and why the patient has been specifically warned. Sublingual nitroglycerin should be available for genuine anginal emergencies but used only if absolutely necessary and with the patient seated or supine. Option E invents a gradient-based threshold (60 mmHg) for nitrate safety in aortic stenosis that does not exist in any clinical guideline; the hemodynamic risk of nitrate-induced preload reduction is present across the spectrum of severe AS severity and is not safely mitigated at gradients between 40 and 60 mmHg.

• Option A: Option A is incorrect: nitrates do not dilate the aortic root or alter the structural anatomy of the stenotic valve; the valve gradient is determined by the fixed orifice area and the flow across it, not by aortic root dimensions.
• Option B: Option B is incorrect: nitrates do not activate the renin-angiotensin system as a primary mechanism and do not cause angiotensin II-mediated coronary vasoconstriction; this mechanism is fabricated and does not represent an established adverse effect of nitrates in any patient population.
• Option C: Option C is incorrect: while hypertrophied ventricles do have increased mass, they typically have impaired diastolic function and reduced compliance — not increased preload reserve. More importantly, the Frank-Starling compensation cannot overcome the fixed obstruction to maintain cardiac output; the mechanism described would require the ability to increase stroke volume, which the stenotic valve prevents.

ANSWER: E

Rationale:

This question asked you to identify the diagnostic limitation of nitroglycerin response and state the more reliable clinical feature for stable angina. Option E is correct: relief of chest pain by sublingual nitroglycerin is a well-recognized but non-specific diagnostic finding. Organic nitrates release nitric oxide, which activates soluble guanylate cyclase and generates cGMP in smooth muscle cells throughout the body — not only in coronary vascular smooth muscle. Esophageal smooth muscle contains the same NO-responsive signaling machinery, and esophageal spasm — which produces midsternal chest pain that can closely mimic angina in character, intensity, and radiation — frequently responds to sublingual nitroglycerin within minutes. This is because the drug relaxes the spastic esophageal segment through the identical pharmacological mechanism that dilates coronary vasculature. Therefore, nitroglycerin response cannot be used as the primary confirmatory feature to distinguish ischemic from esophageal chest pain. The more diagnostically reliable feature in this patient is the exertional pattern: chest tightness that occurs reliably at a predictable level of physical activity (brisk walking or stair climbing), resolves within minutes of stopping activity, and is absent at rest. This pattern reflects the fundamental supply-demand physiology of stable angina — at rest, residual coronary flow through a fixed stenosis meets baseline demand; with exertion, the fixed supply cannot match escalating demand, producing ischemia at a reproducible rate-pressure product threshold. Esophageal spasm does not follow an exertional threshold pattern and is not consistently relieved by rest; it is typically unpredictable, occurring with meals, temperature changes, stress, or spontaneously.

• Option A: Option A is incorrect: sublingual nitroglycerin does not suppress the SA node or reduce heart rate as a primary mechanism; its mechanism is vascular smooth muscle relaxation via NO-cGMP, not cardiac chronotropy; and left arm or jaw radiation, while classically associated with angina, is also not pathognomonic.
• Option B: Option B is incorrect and is the reasoning error that the question is designed to identify: nitroglycerin does affect non-ischemic chest pain generators, specifically the esophagus; the claim that its mechanism is specific to ischemic pathophysiology is incorrect.
• Option C: Option C is incorrect: placebo-mediated pain relief is a real phenomenon but is not the primary established reason for NTG non-specificity in chest pain diagnosis; the mechanistically correct explanation is esophageal smooth muscle relaxation, not placebo effect — and the 80% figure cited is not an established statistic.
• Option D: Option D is incorrect: nitroglycerin does not reduce pain through systemic hypoperfusion of peripheral sensory nerves; this mechanism is fabricated and does not represent any established pharmacological effect; while pre-test probability (determined by age, sex, and symptom characteristics) is important in chest pain evaluation, it is not the answer to why NTG response is specifically unreliable.